C-KJESEidos Therapeutics
genetic disease medicines, TTR stabilization, clinical research
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KJES
C-KJESC-KJESgenetic disease medicines, TTR stabilization, clinical research
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Eidos Therapeutics states that transthyretin (TTR) amyloidosis is a rare, devastating disease with no FDA-approved treatments and that effective therapy should address the disease at its source rather than only manage symptoms. The company presents TTR amyloidosis as a condition driven by misfolded TTR amyloid accumulation, with major clinical forms affecting the heart and peripheral nervous system, and frames its work around developing a novel therapeutic aimed at that root cause.
SourceEidos Therapeutics states that transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs, and that it aims to change this by developing AG10, a novel therapeutic intended to target the disease at its source through TTR stabilization.
SourceEidos Therapeutics states that transthyretin (TTR) amyloidosis is a rare, devastating, progressive, and fatal disease for which existing care mainly manages symptoms rather than the underlying cause, and that the company is working to change this by developing a novel therapeutic aimed at the disease at its source. The page also explicitly states, "We believe all people are created equal, and we reject racism and bigotry."
SourceEidos Therapeutics states that transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs, and expresses the belief that the disease should be targeted at its source through a novel therapeutic approach that stabilizes TTR.
Source